Member Info for EmeraldCarrots

Analysisng samples for cancer biomarkers produced by Parsortix from a standard blood sample. Exactly what Myriad Genetics might be looking for? Also Immatics to find candidates for their Immunotherapy treatments?

One hopes the value of Parsortix will be recognised soon! Beyond ridiculous.

From the RNS:- "CTCs are considered better biomarkers than circulating tumour DNA (ctDNA) for selecting patients for ADC treatment primarily because CTCs allow for the direct analysis of the target protein expression on the cell surface, a critical requirement for ADC efficacy.".

Hang on a tick. So these samples the Roche machine analyses for cancer biomarkers was/is using CtDna in the standard blood samples at the moment? But processing the blood sample first using Parsortix, I presume, means that the sample will contain CTC's with the protein expression (if there are any). Then if that protein expression is one that can be targeted Immunotherapy might be used.

So a much quicker way of finding cancer biomarkers and so candidates for Immunotherapy! Immatics ???

All IMHO.

Sent by CellBxHealth that may/may not contain CTC's and very quickly analyse them for cancer biomarkers. One presumes CellBxHealth (or say Myriad Genetics?) could have say 10 Parsortix machines working 24/7 to produce what 80 or so samples a day from 80 blood draws. Huge amount of time could be saved by the looks. The biggest time would be the Parsortix machine and packaging etc... which might be say 3 hours per sample?

All IMHO.

Interesting developments.

Doc3.

"You’re screaming into a void EC.

16% down.

Little investors likely to be wiped out."

=============================

Only if the competition don't see what is staring them in the face.

Parsortix is proven tech that has a "for sale" sign on it.

Possibly the best machine in the entire World for catching live, intact, uncontaminated CTC's from a standard blood sample.

Means the CTC's CAN undergo DNA, RNA and protein analysis. Indeed anthing that a complete cancer call can.

The sort of analysis CtDna Companies ***are now looking to add to their existing offerings as we know.***.

I don't believe a bid is not being considered at least by, well, several Companies. Logically this must be the case.

All IMHO.

Of lung cancer CtDna analysis. Thus doubling the number of cancer biomarkers found in the test. So why on earth don't they snap up CLBX and do it? I find all this beyond belief. Grail would get better results (by far) and the patients would benefit too, of course. What is wrong with the people running these Companies? Honestly it is quite mad.

All IMHO.

As the most promising next generation technology for clinical applications.".

CtDna analysis Co's ignore this and fall by the wayside. Grail, Myriad Genetics etc..... What's your problem, oh I know. You can't catch live, intact, uncontamonated CTC's for DNA analysis. Oh dear!!! Never mind!!

All IMHO.

CLBX have no clue what CLBX have. No clue at all. From todays RNS:-

· Expert consensus predicts integration of CTC testing into routine clinical practice within 5 years

· CTCs provide distinct and impactful information that is not captured by circulating tumour DNA (ctDNA)

· 40% of the expert panel identified the Parsortix® platform as the most promising next generation technology for clinical applications.

==================================

CtDna anlysis Co's are going to get left behind is they can't add CTC DNA analysis to their offering. Fools.

All IMHO.

CRAZY!!!!!!!!!!!!!!! What in the World are the Pharma and CtDna analysis Plc's doing? They can't all be asleep. CLBX are a sitting, comatose Duck that has a flashing huge neon sign directly above it saying "For Sale, next to nothing cost, massive profit to be made for an established Plc. Become the leader in CTC analysis!".

All IMHO.

From the interim results RNS:-

"ANGLE's ongoing relationship with Immatics is also progressing strongly. Immatics is a clinical-stage biotechnology company developing immunotherapies to create robust and specific anti-tumour responses against solid tumours. ANGLE is currently providing CTC isolation and harvest from study blood samples for downstream molecular analysis across three clinical trials. This includes a Phase 3 study with their lead drug candidate in melanoma."

========================

Difficult to nail down exactly when Immatics started using information obtained using Parsortix. All a bit cloak and dagger, at least pre- 2024. There was this announcement on 16th April 2021:-

https://www.lse.co.uk/rns/AGL/first-large-scale-pharma-services-contract-secured-yul6kl9hzdwjthv.html

but it refers to "prostate cancer and other locally advanced and metastatic solid tumours.". Having said that Immatics in the past were looking more at prostate cancer so it could have been them. At the end of the day Immatics now clearly need the molecular analysis information obtained using Parsortix in their 3 anzu-cel (IMA203) drug trials.

https://immatics.com/our-pipeline/

All IMHO.

Hmm. RNS of 16th April 2021. It must have been Immatics. More than four and a half years ago and Immatics are still using Parsortix in the 3 cancer drug trials, one already if phase 3 and another just moved up to phase 2 after good results. See here:-

https://www.lse.co.uk/rns/AGL/first-large-scale-pharma-services-contract-secured-yul6kl9hzdwjthv.html

=====================

So Immatics have over 4.5 years of data obtained using Parsortix, and it continues. This was and possibly is still not widely known, that is for sure.

Immatics anzu-cel (IMA203):-

https://immatics.com/our-pipeline/

Hmm. RNS of 16th April 2021. It must have been Immatics. More than four and a half years ago and Immatics are still using Parsortix in the 3 cancer drug trials, one already if phase 3 and another just moved up to phase 2 after good results. See here:-

https://www.lse.co.uk/rns/AGL/first-large-scale-pharma-services-contract-secured-yul6kl9hzdwjthv.html

Immatics. Phase II & III trials. Join the dots........2 Nov 2025 14:17

I have been trying to find out why Immatics use Parsortix in 3 of their cancer drug trials. Note one has just moved up to phase 2 and another is already in phase 3. The Parsortix machine was designed to catch circulating tumour cells (CTC's). With Parsortix they are 99% live, intact and uncontaminated. So ideal for any type of analysis, including DNA. You could not have a better sample. So why do Immatics catch them?

What is "Immatics anzu-cel (IMA203)"?

It is s an autologous T-cell therapy for cancers that express the ***PRAME protein***, such as advanced melanoma and uveal melanoma. It involves genetically engineering a patient's own T-cells to recognize and attack cancer cells displaying the PRAME antigen on their surface. The therapy is in a Phase 3 clinical trial (SUPRAME) for advanced melanoma and is designed to provide a more durable response compared to existing treatments in patients who have progressed on checkpoint inhibitors.".

I think they want to look at the CTC's to see if the PRAME PROTEIN is expressed on the CTC's. Also I believe they would be looking at the original solid tumour sample for the same. This would make the candidate ideal for the treatment, would it not? The CTC analysis having the advantage of being up to date, and in some peoples opinion more representative due to this.

What is the process?

"T cells are collected and genetically modified in a laboratory to express a novel, highly specific T-cell receptor that recognizes a PRAME-derived peptide presented by the HLA-A*02:01 molecule on the surface of tumor cells. These "redirected" T cells are then infused back into the patient to initiate a potent anti-tumor response.".

Does Parsortix catch T-Cells and CTC's at the same time?

Yes, some T-cells (a type of leukocyte or white blood cell) are captured incidentally by the Parsortix system, as the isolation method is based purely on physical characteristics (size and deformability) rather than specific biological markers. ***So not only does Parsortix deliver the CTC's, it delivers the very T-Cells Immatics want to genetically change.***.

Also, let's not forget the CTC analysis can be done at any time to see what effect the teatment has on the CTC's, and indeed the T-Cells. So they can see the before, during and after.

It this why CKLBX went up 26.32% Friday 31st October?

All IMHO.

https://immatics.com/our-pipeline/

Interesting. Have a read on CLBX (up 26.32% Friday). Parsortix seems ideal for Immatics needs.

I have been trying to find out why Immatics use Parsortix in 3 of their cancer drug trials. Note one has just moved up to phase 2 and another is already in phase 3. The Parsortix machine was designed to catch circulating tumour cells (CTC's). With Parsortix they are 99% live, intact and uncontaminated. So ideal for any type of analysis, including DNA. You could not have a better sample. So why do Immatics catch them?

What is "Immatics anzu-cel (IMA203)"?

It is s an autologous T-cell therapy for cancers that express the ***PRAME protein***, such as advanced melanoma and uveal melanoma. It involves genetically engineering a patient's own T-cells to recognize and attack cancer cells displaying the PRAME antigen on their surface. The therapy is in a Phase 3 clinical trial (SUPRAME) for advanced melanoma and is designed to provide a more durable response compared to existing treatments in patients who have progressed on checkpoint inhibitors.".

I think they want to look at the CTC's to see if the PRAME PROTEIN is expressed on the CTC's. Also I believe they would be looking at the original solid tumour sample for the same. This would make the candidate ideal for the treatment, would it not? The CTC analysis having the advantage of being up to date, and in some peoples opinion more representative due to this.

What is the process?

"T cells are collected and genetically modified in a laboratory to express a novel, highly specific T-cell receptor that recognizes a PRAME-derived peptide presented by the HLA-A*02:01 molecule on the surface of tumor cells. These "redirected" T cells are then infused back into the patient to initiate a potent anti-tumor response.".

Does Parsortix catch T-Cells and CTC's at the same time?

Yes, some T-cells (a type of leukocyte or white blood cell) are captured incidentally by the Parsortix system, as the isolation method is based purely on physical characteristics (size and deformability) rather than specific biological markers. ***So not only does Parsortix deliver the CTC's, it delivers the very T-Cells Immatics want to genetically change.***.

Also, let's not forget the CTC analysis can be done at any time to see what effect the teatment has on the CTC's, and indeed the T-Cells. So they can see the before, during and after.

It this why CKLBX went up 26.32% Friday 31st October?

All IMHO.

https://immatics.com/our-pipeline/

AI Overview

Yes, some

T-cells (a type of leukocyte or white blood cell) are captured incidentally by the Parsortix system, as the isolation method is based purely on physical characteristics (size and deformability) rather than specific biological markers.

The Parsortix system uses a microfluidic cassette with a progressively narrowing critical gap (typically 6.5 µm) to capture larger, less deformable circulating tumor cells (CTCs) while allowing smaller, more flexible normal blood cells, like T-cells, to pass through.

While the system is highly effective at depleting the vast majority of normal blood cells (up to 100,000-fold depletion of nucleated blood cells), a small number of leukocytes, including T-cells, can be retained in the cassette along with the CTCs. The final harvested sample is not a pure CTC population but is significantly enriched for them.

The presence of these residual white blood cells is expected, and downstream analysis methods often include steps (e.g., specific staining or molecular analysis) to differentiate the captured CTCs from the remaining T-cells and other leukocytes.

FDA applications the situation would be massively better. What's the betting that until now they have prioritised use by the UK's NHS over FDA applications? In my view if the application for the MT-RNR1-ID had gone in 3 months ago the Company would not have been in this mess because USA investors would have pushed the share price up over 2p a share. Maybe data from actual use in the USA IS needed, but I have read it is not???? Data from use in the UK's NHS can be used, provided it is obtained and documented in the correct way, is what I have read. I am extremely unhappy that the application has still not been done with no explanation as to why not. I believe the MT-RNR1-ID will sell like hot cakes in the USA once it has obtained FDA clearance.

All IMHO.

How can the market cap be less than £10m? They work with Immarics, Illumina, Astrazeneca, Eisai, Myriad Genetics etc.

Probably the only Company in the World that offer lung cancer biomarker "dual analysis". Others to follow.

Catching actual live CTC's offers a sample for complete analysis. DNA, protein expression, RNA, everything. Is this why Immatics use Parsortix in 3 of their current drug trials? One in phase 2 and one in phase 3?

More Pharma Co's need to wake up and listen to what this Company can do. It's as if some of the Pharma Companies in the World refuse to acknowledge the facts staring them in the face. Only Illumina have publically confirmed "dual analysis" works and is real! Beggars belief. You can actually find aout TWICE the amount of cancer biomarkers with dual analysis!!! WAKEY WAKEY. Illumina don't make things up!!!!!!!!!!!!!!

All IMHO

Firking longer is it going to take? I would like to speak to Gino in person and have him explain why this application HAS STILL NOT EVEN BEEN MADE! Beggars belief. Now there is a good possibliity of a loan that would take us through to March next year they had better sort it out. I ain't happy at all with the totally ridiculous delay. SORT IT OUT!!!!!!!!!!!!!!!!!!

Correction. "for catching ", not "to catching"

When you have a unique machine that is quite possibly the best in the entire World. AN was holding out for "the deal" and lost. Myriad Genetics have basically struck a deal to find out once and for all what they can do utilising the Parsortix machine. Being able to catch live, intact, uncontaminated circulation tumour cells that are ideal for DNA analysis. Even if they have chemical or antibody-based alternatives to catching CTC's if they decide to use Parsortix they have the actual pure, live CTC, so any future types of analysis that may be needed make using Parsortix "future proof". That is very important.

All IMHO.